Zota Health Care Reports Strong Q2FY27 Revenue Growth and Sequential EBITDA Turnaround
Zota Health Care Ltd · Press Release · 28 Oct 2026, 11:47 pm
Zota Health Care Reports Strong Q2FY27 Revenue Growth and Sequential EBITDA Turnaround Zota Health Care reported a 54.58% YoY rise in consolidated revenue from operations to ₹19,933.14 lakhs for Q2FY27 ending 30th Sep'26, driven by a 76.25% YoY jump in Davaindia sales to ₹16,846.81 lakhs. EBITDA achieved a sharp sequential turnaround to ₹791.72 lakhs (3.97% margin) from a loss of ₹955.40 lakhs in Q1FY27. Davaindia reached 2,840 stores nationwide, generating quarterly GMV of ₹18,791 lakhs. Additionally, the company converted ₹119.52 crore of DHML debt into equity via preferential share allotment.
Original exchange filing (PDF)
More announcements from Zota Health Care Ltd
- Monitoring Agency Report issued by CRISIL Ratings Limited for the utilization of funds raised through Qualified Institutional Placement for the quarter ended September 30, 2026 · 14 Nov 2026
- ZOTA: Zota Health Care Limited has informed the Exchange about Transcript of Earnings Conference Call on Financial Results for the quarter ended September 30, 2026 · 04 Nov 2026
- ZOTA: Zota Health Care Limited has informed the Exchange about Audio Recording Link of Earnings Conference Call on financial results for the quarter and half year ended September 30, 2026 · 29 Oct 2026
- Zota Health Care LImited has informed the Exchange about statement of deviation(s) or variation(s) under Reg. 32 · 28 Oct 2026
- Zota Health Care LImited has informed the Exchange about Investor Presentation · 28 Oct 2026
- ZOTA: Zota Health Care Limited has submitted to the Exchange the Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended on September 30, 2026 · 28 Oct 2026
- ZOTA: Zota Health Care Limited has informed the Exchange about the Intimation of Schedule of Earnings Conference Call on Q2FY27 Results · 29 Oct 2026
- ZOTA HEALTH CARE LIMITED has informed the Exchange about Board Meeting to be held on 28-Oct-2026 to consider and approve the Half Yearly Unaudited Financial results of the Company for the period ended September 2026 and Other business. · 28 Oct 2026
